Literature DB >> 12187314

Acetylcysteine and contrast media nephropathy.

Martin Tepel1, Walter Zidek.   

Abstract

PURPOSE OF REVIEW: Radiographic contrast media are used at an increasing rate for several diagnostic and therapeutic applications. Therefore, contrast agent-induced nephropathy will become more important, including the risk of patient impairment and costs. The prevention of radiographic contrast-induced nephropathy is mandatory. Radiographic contrast agent-induced nephropathy is caused by vasoconstriction-mediated renal medullary ischaemia and direct toxic damage to renal tubular epithelial cells. These effects may be partly mediated by the generation of reactive oxygen species. Data from experimental studies indicate that antioxidants, e.g. acetylcysteine, may prevent radiocontrast-induced nephropathy. RECENT
FINDINGS: Two prospective, randomized, placebo-controlled studies in patients with moderate renal insufficiency confirmed that the prophylactic oral administration of acetylcysteine, at a dose of 600 mg twice a day along with hydration, prevents the reduction in renal function after radiocontrast administration.
SUMMARY: The use of acetylcysteine together with hydration is the treatment of choice to protect against radiographic contrast media-induced nephropathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187314     DOI: 10.1097/00041552-200209000-00005

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  3 in total

Review 1.  Contrast nephropathy.

Authors:  Shereif H Rezkalla
Journal:  Clin Med Res       Date:  2003-10

2.  Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials.

Authors:  Yongchuan Li; Yawei Liu; Lili Fu; Changlin Mei; Bing Dai
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

Review 3.  Nephrotoxicity as a cause of acute kidney injury in children.

Authors:  Ludwig Patzer
Journal:  Pediatr Nephrol       Date:  2008-01-29       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.